Allogene Therapeutics Announces Oral Presentation of Phase
Initial Data Provide Proof-of-Concept for an anti-CD70 AlloCAR T Candidate in Patients with Renal Cell Carcinoma (RCC) Who Received Prior Immune Checkpoint...
Source: globenewswire.com
Stay updated with breaking news from Control Immune Rejection. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Initial Data Provide Proof-of-Concept for an anti-CD70 AlloCAR T Candidate in Patients with Renal Cell Carcinoma (RCC) Who Received Prior Immune Checkpoint...